The Healthcare Outlook: Macro Challenges and Biotech Innovations

93 snips

Sep 18, 2025

Asad Haider, Head of the U.S. Healthcare Business Unit at Goldman Sachs Research, dives into healthcare's recent struggles due to AI shifts and policy uncertainties. Amit Sinha, Head of Life Sciences Investing at Goldman Sachs Asset Management, discusses why private capital is crucial for biotech and highlights groundbreaking advancements in areas like genetics and immunology. Both guests uncover innovative pockets within the industry, from oral obesity treatments to oncology strategies, painting a hopeful picture amid challenges.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Policy Uncertainty Is A Key Drag

Policy overhangs from Washington and regulatory shifts have pressured healthcare multiples and investor appetite.
Clarity on policy or a rotation away from AI would be needed to materially reopen the sector.

INSIGHT

Vaccine Guidance Has Become Unstable

Vaccine policy and personnel changes have created acute uncertainty for COVID and broader vaccine demand.
Shifts in guidelines and state-level mandate removals could meaningfully reduce uptake this season.

INSIGHT

Cuts To NIH Risk Slowing Innovation

Proposed NIH funding cuts could reduce academic-driven R&D and weigh on life-sciences tools demand.
Companies exposed to academic funding already feel the downstream impact in sentiment and revenues.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

While the healthcare sector has lagged behind the broader markets, there are pockets of innovation. Asad Haider, head of the US Healthcare Business Unit in Goldman Sachs Research, and Amit Sinha, head of Life Sciences Investing in Goldman Sachs Asset Management, discuss their outlook for the industry.

This episode was recorded on September 8 and 15, 2025.

The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products. This material may contain forward-looking statements. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs.

A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs.

Disclosures applicable to research with respect to issuers, if any, mentioned herein are available through your Goldman Sachs representative or at http://www.gs.com/research/hedge.html.

Goldman Sachs does not endorse any candidate or any political party.

Learn more about your ad choices. Visit megaphone.fm/adchoices